FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).

David Malka; Florence Castan; Eric Francois; Olivier Bouche; Jaafar Bennouna; Francois Ghiringhelli; Christelle De La Fouchardiere; Christophe Borg; Emmanuelle Samalin; Jean Baptiste Bachet; Jean-Luc Raoul; Frédérique Cvitkovic; Laurent Miglianico; Leila Bengrine-Lefevre; Laetitia Dahan; Cedric Lecaille; Thomas Aparicio; Herve Perrier; Sophie Gourgou; Julien Taïeb;

doi:10.1200/jco.2015.33.15_suppl.4013

FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.4013 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 4013-4013 ◽

Cited By ~ 8

Author(s):

David Malka ◽

Florence Castan ◽

Eric Francois ◽

Olivier Bouche ◽

Jaafar Bennouna ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

Gastroesophageal Adenocarcinoma ◽

First Line Treatment

Download Full-text

First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7591 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7591-7591 ◽

Cited By ~ 2

Author(s):

J. Liang ◽

M. Ahn ◽

J. Kang ◽

Q. Xiu ◽

Y. Chen ◽

...

Keyword(s):

Phase Ii ◽

Advanced Nsclc ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

Never Smoker ◽

First Line Treatment

Download Full-text

Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps178 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS178-TPS178 ◽

Cited By ~ 1

Author(s):

D. Malka ◽

S. Gourgou-Bourgade ◽

J. Emile ◽

P. Laurent-Puig ◽

J. Taïeb

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Egfr Inhibition ◽

Randomized Phase Ii ◽

Gastroesophageal Adenocarcinoma ◽

First Line Treatment

Download Full-text

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial

European Journal of Cancer ◽

10.1016/j.ejca.2019.04.020 ◽

2019 ◽

Vol 115 ◽

pp. 97-106 ◽

Cited By ~ 3

Author(s):

David Malka ◽

Eric François ◽

Frédérique Penault-Llorca ◽

Florence Castan ◽

Olivier Bouché ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Gastroesophageal Adenocarcinoma ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

First Line Treatment

Download Full-text

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Cited By ~ 1

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Cited By ~ 83

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.

10.1158/0008-5472.sabcs11-p5-19-03 ◽

2011 ◽

Cited By ~ 1

Author(s):

WJ Gradishar ◽

D Krasnojon ◽

S Cheporov ◽

AN Makhson ◽

GM Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)

Annals of Oncology ◽

10.1093/annonc/mdy281.154 ◽

2018 ◽

Vol 29 ◽

pp. viii202

Author(s):

A. De Stefano ◽

G. Nasti ◽

A. Febbraro ◽

G. Rosati ◽

F. Giuliani ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

TOMOX compared to FOLFOX4 as first-line treatment in patients (pts) with advanced colorectal cancer (ACRC): Preliminary results of a multicenter randomized phase II trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3599 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3599-3599

Author(s):

C. Grávalos ◽

C. García-Girón ◽

A. I. León ◽

A. Salud ◽

B. Esteban ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Advanced Colorectal Cancer ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Preliminary Results ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text